In short
LIGUFALIMAB is being studied in clinical trials for people with recurrent and/or metastatic squamous cell carcinoma of the head and neck. These trials look at whether it can help improve survival, especially in first-line treatment, and compare it with standard treatment. The main focus is on safety and how well the treatment works in the study population.
Key points
- LIGUFALIMAB is being studied in one Phase 3 clinical trial for recurrent and/or metastatic squamous cell carcinoma of the head and neck. The trial compares ivonescimab plus LIGUFALIMAB, ivonescimab alone, and pembrolizumab. It is focused on first-line treatment in patients who are PD-L1 positive with CPS 1 or higher. The main outcome being measured is overall survival. The study is authorised and plans to include 700 participants.
Trial overview
One authorised Phase 3 trial is studying LIGUFALIMAB in people with recurrent and/or metastatic squamous cell carcinoma of the head and neck. This is an interventional study, which means the researchers give study treatment and then measure the results.
Study design and treatment groups
The trial compares ivonescimab plus LIGUFALIMAB with pembrolizumab, and also compares ivonescimab alone with pembrolizumab. The study summary says this is for first-line treatment, meaning the first treatment given for this cancer.
The trial includes a treatment group with LIGUFALIMAB given as an intravenous infusion, which means it is given through a vein. The source also lists pembrolizumab and ivonescimab as the other study treatments.
Who can participate
The study is aimed at patients with recurrent and/or metastatic head and neck squamous cell carcinoma. The brief summary also says the population is PD-L1 positive with CPS 1 or higher. PD-L1 positive means the tumor has a marker that can help guide treatment choice, and CPS is a score used to measure that marker.
What is being measured
The main outcome is overall survival. Overall survival means how long patients live after starting treatment, and it is a key way to see whether a cancer treatment helps people live longer.
Trial status and size
The trial status is Authorised. The planned enrollment is 700 participants, showing that this is a large study.